The Dame Jillian Sackler Distinguished Lecture on Global Health Issues with Dr. Michael J. Sofia

Michael J. Sofia - Speaker
Ph.D., Chief Scientific Officer, Arbutus Biopharma

Michael J. Sofia, Ph.D. is co-founder and Chief Scientific Officer of Arbutus Biopharma, Inc. a company focused on the discovery and development of therapies to treat hepatitis B. Previously Dr. Sofia was Sr. Vice President of Chemistry at Pharmasset, Inc. Dr. Sofia has also held research and research management positions at Gilead Sciences, Bristol-Myers Squibb, Transcell Technologies and Eli Lilly and Company

Dr. Sofia received his BA in chemistry from Cornell University, his Ph.D. from the University of Illinois and was a postdoctoral fellow at Columbia University.

Dr. Sofia has introduced numerous drugs into clinical development for the treatment of infectious diseases and inflammatory diseases.  He has authored over 100 publications, 12 book chapters and numerous abstracts and is an inventor on more than 53 US patents.  He has been an invited speaker at over 80 national and international conferences. He is the principle inventor of sofosbuvir (Sovaldiâ, Harvoniâ, Epclusaâ and Voseviâ) currently marketed as the backbone of treatment for the cure of HCV infection. 

Dr. Sofia has received numerous awards for his work on hepatitis C including the 2015 Economist Innovation Award, the 2015 ACS Heroes of Chemistry Award, 2016 IUPAC-Richter Prize, the 2016 Lasker-Debakey Award in Clinical Medical Research, the 2017 Gertrude Elion Award from the International Society for Antiviral Research,and the New Jersey Science and Technology Medal. In 2017 he was inducted into the American Chemical Society Medicinal Chemistry Hall of Fame.

FPA's Elbrun Kimmelman Distinguished Lecture on U.S.-India Relations

Apr 30, 2024